

Centering Patients in Perinatal Care

June 3, 2025 | 1830–2000 PT



THE UNIVERSITY OF BRITISH COLUMBIA

Continuing Professional Development

Faculty of Medicine

LAND ACKNOWLEDGMENT

We acknowledge that UBC CPD work on the traditional, ancestral and unceded territory of the Skwxwú7mesh (Squamish), xʷməθkwəy̓əm (Musqueam), and Səlílwətaʔ/Selilwitulh (Tsleil-Waututh) Nations.



UBC CPD
Medicine
CONTINUING
PROFESSIONAL
DEVELOPMENT

What is your relationship to the territory or the land that you're on?

FUNDING ACKNOWLEDGEMENT

Funding for this webinar has been provided by the Perinatal Community of Practice, an initiative of the Shared Care Committee and Joint Collaborative Committees.



Joint
Collaborative
Committees



UBC CPD
Medicine
CONTINUING
PROFESSIONAL
DEVELOPMENT

LEARNING OBJECTIVES

1. Apply strategies to support and facilitate immediate skin-to-skin contact in the operating room following Cesarean delivery.
2. Integrate current vaccination guidelines into routine prenatal care to ensure timely and effective immunization of pregnant individuals.
3. Determine the most appropriate form, route and timing of iron supplementation during pregnancy based on individual patient needs and clinical evidence.



UBC CPD
Medicine
CONTINUING
PROFESSIONAL
DEVELOPMENT

DISCLOSURES

Speakers

- **Dr. Tessa Chaworth-Musters:** Has received honoraria for speaking from UBC CPD. Is an employee of Provincial Health Services Authority. *Mitigating potential bias:* Peer review of slides prior to presentation.
- **Dr. Brian Conway:** Has received honoraria for presentations from Pfizer Canada. Has received honoraria for presentations, participated in advisory boards, and received funding for grants, research or clinical trials from AbbVie, Astra Zeneca, Gilead Sciences, GSK, Indivior Canada, Merck, Moderna, Sanofi Pasteur, Seqirus, and ViiV Healthcare. *Mitigating potential bias:* Dr. Conway will present fair-balanced literature-based information.
- **Cindy Barton, Dr. Anna Looker, Dr. Andrea Steyne & Dr. Julie Wood (moderator):** Nothing to disclose



UBC CPD
Medicine
CONTINUING
PROFESSIONAL
DEVELOPMENT

DISCLOSURES

Planning Team

- **Dr. Bruce Hobson:** Has received funding from UBC CPD, Doctors of BC, PHSA, PainBC, Cowichan Valley Division of FP, Qathet Division of FP as a Medical Lead, Director, and Committee Member. There is **no potential conflict of interest** between this funding and this webinar.
- **Dr. Shelley Ross:** Has received funding from the Federation of Medical Women of Canada Pfizer related to RSV advocacy. There is **no potential conflict of interest** between this funding and this webinar.
- **Stephanie Din, Caldon Saunders:** Are employees of UBC CPD.



UBC CPD
Medicine
CONTINUING
PROFESSIONAL
DEVELOPMENT



Skin-to-Skin for Caesarean Section: Within Five Minutes of Delivery and Continuously Throughout the Golden Hour

SQi SPREADING
QUALITY
IMPROVEMENT
Specialist Services Committee

Dr. Andrea Steyn, Anesthesiologist and
Cynthia Barton, Manager, Clinical Operations

Land Acknowledgement

We would like to acknowledge that this project was completed in Penticton which is the traditional, ancestral, and unceded territories of the Syilx (Saay-ilks) Nation where we live, learn, collaborate, work together and welcome the next generation.

Disclosures

Relationships with commercial interests

Grants: None

Speakers Bureau/ Honoraria: None

Consulting Fees: None

Other: None

Spreading Quality Improvement



Salmon Arm - SLGH

Skin-to Skin in Under 5 minutes
in the Operating Room and
within 5 minutes of arrival in PAR



Penticton - PRH

To elevate practice by delivering
skin-to-skin within 5 minutes of
operative delivery and
throughout the Golden Hour



Trail - KBRH

Skin-to-Skin in Under 5
minutes in the Operating
Room and continuously
throughout the Golden Hour.



Elevating Skin-to-Skin in Operative Deliveries

Dr. Andrea Steyn, Anesthesiologist
Cynthia Barton, Clinical Operations Director



Enhancing
Maternal Baby
Wellbeing
Through Skin-to-
Skin in Operative
Births



Skin-to-Skin With
Your Baby During
Caesarian
Section – What to
Expect

Thank you



Pregnancy: A unique Opportunity to Vaccinate

Brian Conway MD, FRCPC

Medical Director, Vancouver ID Centre

Adjunct Professor, Faculty of health Sciences

Simon Fraser University

SPEAKER DISCLOSURES

- Dr Brian Conway, MD, FRCPC
- Relationships with financial interests:
 - Grants/Research Support: AbbVie, Astra Zeneca, Gilead Sciences, GSK, Indivior Canada, Merck, Moderna, Sanofi Pasteur, Seqirus, and ViiV Healthcare
 - Speakers' Bureau/Honoraria: AbbVie, Astra Zeneca, Gilead Sciences, GSK, Indivior Canada, Merck, Moderna, Pfizer Canada, Sanofi Pasteur, Seqirus, and ViiV Healthcare
 - Consulting Fees: AbbVie, Astra Zeneca, Gilead Sciences, GSK, Indivior Canada, Merck, Moderna, Sanofi Pasteur, Seqirus, and ViiV Healthcare
 - Full editorial control of this presentation resides with **ME! OK!!!!**

Introduction

- Protects pregnant women from infections that may affect pregnancy outcome
- Protects infants (transplacental transfer of IgG) for 4-6 weeks after birth
- No theoretical risk of adverse fetal effects of non-live vaccines
- All live vaccine contraindicated

Recommended Vaccines During Pregnancy

- All routine Inactivated vaccines
- HPV vaccine contraindicated due to lack of data, but this may change
- Tdap: to be given ideally between weeks 27-32, but can be given in 2nd trimester
- Influenza vaccine: inactivated, at all stages of pregnancy
- MMR/varicella: contraindicated (live vaccines)

Recommended Vaccines During Pregnancy

- Other vaccines
 - mRNA COVID-19 vaccine
 - HBV (if non-immune and at risk; severe consequences of acute HBV in pregnancy)
 - HAV (if at risk; severe consequences of acute HAV in pregnancy)
 - Meningococcal vaccine (if outbreaks or asplenic)
 - Pneumococcal vaccine
 - Travel vaccines: yellow fever
- Household contacts
 - Influenza and to a lesser extent COVID

Maternal RSV vaccine approved in Canada

	RSVPreF (Abrysvo™)
Type of vaccine	Recombinant RSVPreF A and preF B (bivalent)
Adjuvanted?	No
Administration	Single dose, IM
RSV target(s)	RSV-A, RSV-B
Amount of antigen delivered per dose	60 mcg RSVPreF-A 60 mcg RSVPreF-B


MATISSE: Primary endpoints, vaccine efficacy by cumulative days after infant birth^{1,2}

Maternal vaccine group (as randomized) ^{1,2}			
RSV-positive severe medically attended LRTI	RSVpreF 120 µg (N ^a =3495)	Placebo (N ^a =3480)	Vaccine efficacy, ^b % (CI ^c)
	Number of cases (%)	Number of cases (%)	
Time interval			
90 days after birth	6 (0.2)	33 (0.9)	81.8 (40.6, 96.3)
120 days after birth	12 (0.3)	46 (1.3)	73.9 (45.6, 88.8)
150 days after birth	16 (0.5)	55 (1.6)	70.9 (44.5, 85.9)
180 days after birth	19 (0.5)	62 (1.8)	69.4 (44.3, 84.1)
RSV-positive medically attended LRTI			
Time interval	Number of cases (%)	Number of cases (%)	Vaccine efficacy, ^b % (CI ^c)
90 days after birth	24 (0.7)	56 (1.6)	57.1 (14.7, 79.8)
120 days after birth	35 (1.0)	81 (2.3)	56.8 (31.2, 73.5)
150 days after birth	47 (1.3)	99 (2.8)	52.5 (28.7, 68.9)
180 days after birth	57 (1.6)	117 (3.4)	51.3 (29.4, 66.8)

CI, confidence interval; LRTI, lower respiratory tract illness; RSV, respiratory syncytial virus; RSVpreF, respiratory syncytial virus prefusion F.

^an=number of participants (at risk) in the specified group. These values were used as the denominators for the percentage calculations.^{1,2} ^bVaccine efficacy was calculated as $1 - [P / (1 - P)]$, in which P is the number of cases in the RSVpreF group divided by the total number of cases. The CI was adjusted using Bonferroni procedure and accounting for the primary end points results.^{1,2} ^c99.5% CI for 90 days and 97.58% CI for 120/150/180 days; CI LB>20% for all time points. 1. Munjal I. Presented at: ACIP 2023; February 23, 2023; Atlanta, GA. 2. Kampmann B, et al. *N Engl J Med*. 2023;388(16):1451-1464.

Nirsevimab (Beyfortus™) monoclonal antibody



**Inhibits conformational shift
of preF protein, preventing viral
membrane fusion**


- Highly potent recombinant human IgG1 kappa monoclonal antibody (MAb)
- Targets highly conserved epitope on prefusion RSV F protein (site Ø)
- Indicated for prevention of RSV lower respiratory tract disease in neonates and infants during their first RSV season, and children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season
- Once per season fixed intramuscular dosing
- Flexible dosing: at birth or just prior to RSV season

MELODY -

Primary and secondary efficacy endpoints


Primary endpoint:

Medically attended LRTI through Day 150
Efficacy, **74.5%** (95% CI 49.6 to 87.1; $P < 0.001$)



Secondary endpoint:

Hospitalization for LRTI through Day 150
Efficacy, **62.1%** (95% CI -8.6 to 86.8; $P = 0.07$)



What do the guidelines say?

Society of Obstetricians and Gynaecologists of Canada (SOGC) – Statement published July 18th, 2024:

1

Clinicians should counsel pregnant patients about the risks of RSV infections in the newborn.

2

Maternal vaccination with RSVpreF and infant administration of nirsevimab are both effective in reducing the burden of RSV disease and hospitalization in newborns aged ≤ 6 months.

- *If both are available, nirsevimab is currently the 1st-line recommended option*
- *If there is no expected supply of nirsevimab or if the pregnant patient declines infant immunization, maternal RSV vaccination should be offered between 32+0 and 36+6 weeks*

What do the guidelines say? (cont'd)

Society of Obstetricians and Gynaecologists of Canada (SOGC) – Statement published July 18th, 2024:

3

Dual immunization of the newborn through administration of both maternal immunization during pregnancy with RSVpreF and infant monoclonal antibody has not been studied is not recommended.

4

At a healthcare systems level, SOGC supports the universal RSV infant immunization program recommended by the National Advisory Committee on Immunization (NACI).

- *Provinces and territories should work to provide a universal program focusing on cost-effectiveness and equitable access for the most marginalized and remote populations*

Availability of Nirsevimab in British Columbia

Monoclonal antibodies were available for most infants in BC during the 2024-2025 RSV season.

Currently, these medications are available only to certain infants and young children through the BC Infant Respiratory Syncytial Virus (RSV) Immunoprophylaxis Program, who meet specific criteria, such as:

- Young, premature babies with chronic medical conditions.
- Infants and young children with major heart or lung conditions.
- Infants living in some remote communities where healthcare access is more limited.
- **Cost:** These medications are free for children who are eligible through the BC RSV Immunoprophylaxis Program. They are not available for private purchase.

RSV vaccine for pregnant people in British Columbia



Timing: The vaccine is given just before or during the RSV season, between weeks 32 and the end of 36 weeks of pregnancy (up until 36 weeks and 6 days). For the best protection, it's important to get the vaccine at least two weeks before birth so the antibodies have enough time to reach the baby.

Safety: ABRYSCO™ is an inactivated (non-live) vaccine that is safe for pregnant people and their developing babies. It is the only vaccine approved for use in pregnancy that has been intentionally tested in pregnant people during clinical trials. Other RSV vaccines are not approved for use in pregnancy.


Cost: The vaccine is not free (it costs about \$300) and can be purchased at select pharmacies.

Pumping Iron in Pregnancy

A Patient Centered Approach



Centering patients in Perinatal Care - 3 June 2025
Tessa Chaworth-Musters



Disclosures:


Relationships with Commercial Interests:

- Grants/Research Support: None
- Speakers Honoraria: UBC CPD
- Consulting Fees: None
- Employee: Provincial Health Services Association

Learning objectives

At the end of this talk, I hope you will be able to:

1. Define anemia & iron deficiency in pregnancy
2. Confidently prescribe oral iron
3. Determine when to consider IV iron in pregnancy
4. Distinguish between relevant IV iron preparations approved by Health Canada



Review Article

The misogyny of iron deficiency

C. Dugan,¹ B. MacLean,¹ K. Cabolis,² S. Abeyesiri,³ A. Khong,⁴ M. Sajic⁴ and T. Richards⁵ on behalf of the Women's Health research Collaborative*

¹ PhD Student, ² Professor, Division of Surge
³ PhD Student, ⁴ Senior Researcher, Depart
Institute of Neurology, London, UK
Institute of Clinical Trials?

Toronto
Australia, Perth, Australia
University College London Quee
London, UK

Ontario's new iron deficiency guidelines change lives: doctors

Changing minimum to 30 µg/l will mean earlier detection, treatment

Lane Harrison · CBC News · Posted: Sep 09, 2024 4:00 AM EDT | Last Updated:



Apple News+

Why iron deficiency is more common – and more serious – than you think

Read now in National Geographic

The New York Times

More Than a Third of Women Under 50 Are Iron-Deficient

The condition can cause fatigue and other symptoms but is rarely tested for. Here's what to know.



Marta Monteiro

How do we define anemia & iron deficiency in pregnancy?



Population	Haemoglobin concentration (g/L)			
	No anaemia	Mild anaemia	Moderate anaemia	Severe anaemia
Pregnancy				
First trimester	≥110	100–109	70–99	<70
Second trimester	≥105	95–104	70–94	<70
Third trimester	? ≥110	100–109	70–99	<70

Ferritin	<30	Deficiency
	30-50	Depletion
	>100	Normal stores

} Non-pregnant adults
Unclear in pregnancy

LISTED OUTCOMES ASSOCIATED WITH **MODERATE/SEVERE** (Hgb <100) MATERNAL ANEMIA



Pregnancy

Severe Maternal Morbidity
Blood transfusion
PPH - increased atony
Infection
Depression
C/S



Newborn


SGA
Low Birth Weight
Preterm delivery
Low APGAR (<5 at 1 min)
Fetal Distress
NICU Admission
Iron deficiency at birth



Children


?impaired
neurodevelopment

heavy menstrual
bleeding
food insecurity
health literacy



iron requirements
peak in third
trimester

blood loss at delivery & breastfeeding



1st trimester more relevant than 3rd trimester iron deficiency for adverse outcomes



WHEN TO TEST

BC Ministry of Health & Perinatal Services BC recommend screening **everyone** for iron deficiency if: preconception, first trimester, breastfeeding or symptomatic.



WHEN TO START A DEDICATED IRON SUPPLEMENT

Ferritin <30

Discuss values for treatment if ferritin $<50-100$

Preconception, after nausea / vomiting resolves, with GDM screen, postpartum!



WHEN TO STOP

Continue treatment for minimum 3-6 months postpartum or until ferritin >100 .

IRON SUPPLEMENTS

A guide for midwives

Oral iron supplements are available in a range of formulations. Amount of elemental iron (iron available for absorption) and rate of absorption varies by formulation. The table below lists elemental iron content for a selection of popular oral formulations and estimated cost of treatment at a standard therapeutic dose of 100 mg elemental iron per day. Information in this handout is based on best available sources and is as complete as possible. Cost estimates are approximate and based on listed prices at major retailers (2015).

IRON SUPPLEMENTS						
A guide for midwives						
FerroUS SALTS						
Formulation	Brand name / Manufacturer	Dose	elemental iron/dose	Amt needed to reach 100 mg/day	One month treatment (100 mg/day) Cost	Notes
Ferrous Gluconate	Iron 50 mg Timed Release / Jamieson	50 mg	50 mg	2 capsules	\$9.96	Enteric-coated
	Ferrous Gluconate / Life	306 mg	35 mg	3 tablets	\$4.76	Enteric-coated
	Floradix Iron Tablet / Salus	~ 25 mg	10 mg	10 tablets	\$82.46	B6, B12, C, riboflavin, thiamine
	Floradix / Salus	10 mL	10 mg	100 mL syrup	\$251.88	B6, B12, C, riboflavin, thiamine
	Floravit / Salus	10 mL	10 mg	100 mL syrup	\$26.81	
Ferrous Sulphate	Ferodan / Odon	5 mL	30 mg	15 mL syrup	\$706.93	
	Spatone Pur-Absorb Iron / Nelsons Bach USA	50 mL	5 mg	20 liquid sachets	\$5.99	Enteric-coated
	Ferrous Sulfate / Life	300 mg	60 mg	2 tablets	\$23.19	
	Ferrotrate / Nutrilchem	137 mg	27 mg	4 capsules	\$12.65	
	Palafer / Valeant	300 mg	100 mg	1 capsule	\$22.19	C, Folate
Ferrous Fumarate	Palafer / Valeant	5 mL	100 mg	1 capsule	\$19.99	
	Palafer CI Prenatal / Valeant	300 mg	100 mg	1 capsule	\$4.19	
	Ferrous Fumarate / Life	200 mg	65.7 mg	2 tablets	\$7.65	B12, C, folate, manganese
	Euro Fer / Euro-Pharm	300 mg	100 mg	1 capsule	\$8.85	
	Iron Factors / Natural Factors	~ 300 mg	35 mg	3 capsules		
FERRIC SALTS						
Formulation	Brand name / Manufacturer	Dose	Elemental iron/dose	Amt needed to reach 100 mg/day	One month treatment (100 mg/day) Cost	Notes
Ferric Pyrophosphate	IRONomart / Lorna Vanderhaeghe	~ 20 mg	15 mg	6 capsules	\$58.47	folate, riboflavin
	IRONomart Liquid / Lorna Vanderhaeghe	5 mL	10 mg	50 mL syrup	\$110.88	B6, B12, C, folate, copper
	Ortho Iron / AOR	358 mg	30 mg	3 capsules	\$112.47	B6, B12, C, folate, thiamine, riboflavin, niacinamide
	Hemoplex Liquid / Nu-Life	10 mL	10 mg	100 mL syrup	\$140.40	

V Vegetarian
 Vo Vegan
 Vx NOT vegetarian

ABBREVIATIONS
 GF Gluten-free
 DF Dairy-free
 LF Lactose-free
 SF Soy-free

WF Wheat-free
 YF Yeast-free
 K Kosher
 H Halal

Maximizing iron tolerability

• Offer clients a lower starting dose (50-80 mg/day). Build to a therapeutic dose (100-200 mg/day) over five days OR offer two weeks of low dose and test for response. Increase dose PRN.
 • Iron absorption is best taken on an empty stomach. GI side effects may be reduced when taken with food.
 • Iron bed may reduce GI upset.

Maximizing iron absorption

- Take 200 mg of vitamin C for 30 mg of iron. Vitamin C is often added to iron supplements, but rarely in amounts sufficient to aid iron absorption.
- Avoid calcium within one to two hours of taking iron supplements (dairy, antacids, or other supplements).
- Avoid coffee and black tea for one to two hours after taking iron.
- Avoid enteric-coated supplements. Enteric coating decreases GI side effect but also interferes with absorption.

Prescribing iron

Writing a prescription for over-the-counter products like iron or prenatal vitamins may allow for coverage by extended benefits plans and the Ontario Drug Benefits Program.

Rx: Ferrous fumarate 200 mg 100 tabs
 2x daily between meals
 Refill X2
 midwife signature
 registration #

YOU HAVE IRON DEFICIENCY (AND YOU'RE PREGNANT)



01 What is Iron Deficiency?

Iron is an essential mineral that your body needs for growth and development. It is an important component of hemoglobin, a protein in red blood cells that transports oxygen around the body. When your body does not have enough iron, your hemoglobin levels can drop below normal, and your organs are unable to get the adequate amount of oxygen they require. This condition is known as **iron deficiency anemia**. It is the most common form of anemia. A lack of iron can lead to many symptoms and impair your ability to do normal daily activities.



02 Why is iron important during pregnancy?

30% Iron deficiency occurs in over 30% of pregnancies in Canada. Symptoms of iron deficiency are often dismissed as normal pregnancy symptoms. Many patients are left untreated, which **increases the health risks for both mom** (heavy bleeding at delivery, need for blood transfusion) **and baby** (smaller size, preterm birth). There is even some information that it may have long-term effects on the baby's brain development.

04 What are my treatment options?

Iron deficiency can be treated.

Oral iron supplements, taken by mouth and absorbed through the digestive tract, are the first choice in treatment for most patients. Iron supplements are "over the counter" and do not require a prescription. There are many iron preparations available including pills, capsules, drops, and extended-release tablets (Table 1). If you have iron deficiency in pregnancy, prenatal vitamins **do not have enough iron** to correct the deficiency and an additional iron supplement will be required. Typically, adults will need to take between 60-120mg of elemental iron per day.

Intravenous (IV) iron infusion is an alternative treatment option to oral iron that can supplement iron at a much faster rate. It is **safe and effective in the second and third trimester and during breastfeeding**. It may be recommended by your doctor as an alternative option in cases where oral iron is not tolerated, not able to correct iron deficiency, or where iron is needed quickly (like close to the time of birth).

03 Will eating more iron-rich foods help?

A dietary strategy works best for **prevention** rather than **treatment** of iron deficiency.

While eating an iron-rich diet can help to prevent iron deficiency anemia, an average person's intake of **dietary iron is not enough** to correct the condition once it has developed. There are two main sources of iron in our diets: animal (heme iron) and plant (non-heme).

Heme iron-containing foods	Lean red meat, chicken, fish, pork, shrimp
Non-heme iron-containing foods	Beans, leafy greens, dried fruits, eggs, wholemeal bread, iron-fortified breakfast cereals

The recommended daily intake of elemental iron in pregnant women is 27 mg per day.

Table 1: Some commonly recommended oral iron products

Oral iron	Brand Name	Daily or alternate day dosing	Dose, mg	Elemental iron, mg/tab	Daily estimated cost*
Ferrous gluconate	Floradix®, Floravit®	1 - 2 tablets	300	35	\$0.10
Ferrous fumarate	Palafar®, Eurofer®	1 tablet	300	100	\$0.10

*Cost will vary depending on geographic location and subject to change.

05 How should I take my oral iron?

MAXIMIZE IRON ABSORPTION

Take your iron supplements on an **empty stomach** (preferably 1-2 hours before a meal) with vitamin C.

Vitamin C can be in the form of a supplement (250-500mg) or a citrus drink (e.g. orange juice).

AVOID CERTAIN FOODS AND MEDICATIONS

Avoid these **within 1 hour** of oral iron:

- Calcium
- Proton pump inhibitors (e.g. omeprazole, pantoprazole)
- Antacids (e.g. Tums, Gaviscon, famotidine)
- Thyroid medication
- Tea, coffee, milk
- Soy
- Eggs

WATER AND FIBRE

Consume lots of water and fibre with your iron to reduce constipation and cramping side effects. If you have constipation, try taking a laxative such as Senokot or PEG.

If the side effects of oral iron are very bothersome, you can try taking your iron supplement **EVERY OTHER DAY**.

06 What are the side effects of oral iron?

- Dark stools
- Stomach discomfort
- Nausea
- Diarrhea
- Constipation

Side effects can be lessened by:



Drinking lots of water



Increasing fibre in diet (e.g. Metamucil, bran, vegetables)



Taking iron before bedtime



Taking a stool softener



Changing to every other day dosing

These side effects are bothersome but not dangerous.

07 What happens now?

It is recommended that you repeat your blood tests 2-4 weeks after the start of your iron supplement to ensure that you are responding to treatment. Once your hemoglobin and iron levels are normalized, you may need to take the iron supplement for another six months.

For more information, talk to your doctor.

Always consult with your doctor about the treatment plan that is right for you.





Lab based experiments vs
clinical studies / “IRL”

Emphasis on overall adherence
→ avoid getting lost in the weeds

The best iron is the one taken

Considerations for parenteral iron:

- Advanced gestational age
- Moderate - severe anemia
- Symptomatic
- Malabsorption syndromes
 - active inflammatory bowel disease, gastric-bypass



Intolerant to oral iron despite optimization:

- 3x a week dosing
- formulation change
- start low & go slow
- take with food or at night

Persistent anemia despite good trial of oral iron (takes time in pregnancy!)

- don't expect increase in ferritin

Relevant IV iron formulations : Health Canada

Name <i>Trade Name</i>	Iron Sucrose <i>Venofer</i>	Iron Isomaltoside / Ferric Derisomaltose <i>Monoferic</i>	Ferric Carboxymaltose <i>Ferinject</i> Not yet on BC pharmacare formulary
Max dose / visit	300mg	1500mg	1000 mg
Infusion time	2-4 hours	<90 mins	30-60 mins
Experience in Pregnancy	Extensively Published	Increasing >1600 doses in trial setting	Extensively Published
Points of Note	Unclear risk of harm in first trimester	Highest rates of hypersensitivity reactions	Hypophosphatemia in some populations
Product Monograph	“use in pregnancy when benefits outweigh risks”	use after >16 weeks GA if benefit outweigh risks	use after >16 weeks GA if benefit outweigh risks
Cost	\$202.50 / 900mg 3 visits	\$550 / 1000 mg 1 visit	TBD

Relevant IV iron formulations : Health Canada

Name <i>Trade Name</i>	Iron Sucrose <i>Venofer</i>	Iron Isomaltoside / Ferric Derisomaltose <i>Monoferic</i>	Ferric Carboxymaltose <i>Ferinject</i> Not yet on BC pharmacare formulary
Max dose / visit	300mg	1500mg	1000 mg
Infusion time	2-4 hours	<90 mins	30-60 mins
Experience in Pregnancy	Extensively Published	Increasing >1600 doses in trial setting	Extensively Published
Points of Note	Unclear risk of harm in first trimester	Highest rates of hypersensitivity reactions	Hypophosphatemia in some populations
Product Monograph	“use in pregnancy when benefits outweigh risks”	use after >16 weeks GA if benefit outweigh risks	use after >16 weeks GA if benefit outweigh risks
Cost	\$202.50 / 900mg 3 visits	\$550 / 1000 mg 1 visit	TBD

Points of note for IV iron preparations

<p>Iron Isomaltoside / Ferric Derisomaltose <i>Monoferic</i></p> <p>Hypersensitivity Reaction (Fishbane)</p>	<p>Ferric Carboxymaltose <i>Ferinject</i> Not yet on BC pharmacare formulary</p> <p>Hypophosphatemia</p>
<p><u>Trial data in pregnancy :</u> India (n=1454) 23.4% infusion-related reaction 8.9% required treatment 1.9% moderate/severe reaction 0.0% infusion related serious adverse event</p> <p>Denmark (n=100) Not published</p> <p>Stop infusion, monitor until symptoms resolve. Restart at 50% rate after >15 mins. Consider cetirizine or ondansetron.</p>	<p><u>Trial data in pregnancy :</u> India (n=1451) 4.3% 2 weeks after infusion 2.5% 9 weeks after infusion</p> <p>Nadir at 1-2 weeks post infusion Clinical significance not clear Routine screening not currently recommended in healthy pregnant patient receiving x1 dose</p> <p>Identified risk factors in general population:</p> <ul style="list-style-type: none"> - Ferritin <10 - Normal kidney function / body weight - Low baseline Phos - Repeat or high doses


Final thoughts...

We can (& should) improve hemoglobin and ferritin in everyone.

Start oral iron early - preconception! after nausea/vomiting!
& continue postpartum until replete.

Consider IV iron in pregnancy in setting of moderate/severe anemia,
especially at late GA or oral not tolerated.

It is unclear if the correction of
mild anemia or iron deficiency without anemia
improves perinatal outcomes.



QUESTIONS?

THANK YOU:
OBIM Team

CONTACT:
tessa.chaworth@cw.bc.ca



©2016 The Awkward Yeti



theAwkwardYeti.com

